| name | endo-ace-arb-ccb-htn |
| description | Recommends ACE inhibitors, ARBs, or calcium channel blockers as first-line hypertension therapy rather than β‑adrenergic blockers in obese patients with type 2 diabetes. Triggers include when a clinician asks, 'What antihypertensive should I start for this obese patient with T2DM to avoid weight gain?' or 'Should I avoid β‑blockers in this patient with diabetes and hypertension?' |
Prefer ACE/ARB/CCB over β‑blockers for hypertension in T2DM obese
STEP 1 — Gather Information
Confirm diagnosis of type 2 diabetes, obesity (BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with comorbidity), and presence of hypertension; assess for contraindications to ACEI/ARB/CCB (pregnancy, bilateral renal artery stenosis, hyperkalemia, angioedema history) and for compelling β‑blocker indications (HFrEF, post‑MI, angina).
STEP 2 — Rule In / Rule Out
If a compelling β‑blocker indication exists (e.g., HFrEF, recent MI), consider β‑blocker; otherwise, rule out β‑blocker as first‑line and proceed to ACE/ARB/CCB selection.
STEP 3 — Classify or Stratify
Choose agent based on comorbidities: ACEI or ARB preferred if albuminuria, CKD, or heart failure with preserved EF; CCB preferred if edema risk is low and patient needs avoidance of cough/hyperkalemia; avoid ACEI/ARB in pregnancy or bilateral stenosis.
STEP 4 — Decide
Initiate the selected ACEI, ARB, or CCB at low dose, titrate to target BP; document avoidance of β‑blocker unless a compelling indication arises later.
Clinical Guardrails / Mimics / Pitfalls
Do not use β‑blockers solely for hypertension in obese T2DM due to risk of weight gain, worsened insulin resistance, and masking hypoglycemia symptoms; avoid non‑selective β‑blockers without vasodilating properties; do not combine ACEI and ARB; monitor for ACEI‑related cough or angioedema, ARB‑related hyperkalemia, and CCB‑related peripheral edema.
Concrete Clinical Example
A 58‑year‑old woman with T2DM, BMI 34 kg/m², BP 152/96 mmHg, no heart failure or post‑MI, is started on lisinopril 10 mg daily after confirming no contraindications; β‑blocker is avoided to limit weight gain and insulin resistance.
Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415
